CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter’s five forces analysis
3.4.Top player positioning
3.5.Market dynamics
3.5.1.Drivers
3.5.2.Restraints
3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market
CHAPTER 4: AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY INDICATION
4.1 Overview
4.1.1 Market size and forecast
4.2 Phenylketonuria
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market analysis by country
4.3 Maple syrup urine disease
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market analysis by country
4.4 Citrullinemia
4.4.1 Key market trends, growth factors and opportunities
4.4.2 Market size and forecast, by region
4.4.3 Market analysis by country
4.5 Homocystinuria
4.5.1 Key market trends, growth factors and opportunities
4.5.2 Market size and forecast, by region
4.5.3 Market analysis by country
4.6 Argininosuccinic aciduria
4.6.1 Key market trends, growth factors and opportunities
4.6.2 Market size and forecast, by region
4.6.3 Market analysis by country
CHAPTER 5: AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY PRODUCT
5.1 Overview
5.1.1 Market size and forecast
5.2 Folic Acid
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market analysis by country
5.3 Vitamin B6 and B12
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market analysis by country
5.4 Arginine
5.4.1 Key market trends, growth factors and opportunities
5.4.2 Market size and forecast, by region
5.4.3 Market analysis by country
5.5 Thiamine
5.5.1 Key market trends, growth factors and opportunities
5.5.2 Market size and forecast, by region
5.5.3 Market analysis by country
5.6 Betaine
5.6.1 Key market trends, growth factors and opportunities
5.6.2 Market size and forecast, by region
5.6.3 Market analysis by country
5.7 Sapropterin
5.7.1 Key market trends, growth factors and opportunities
5.7.2 Market size and forecast, by region
5.7.3 Market analysis by country
5.8 Others
5.8.1 Key market trends, growth factors and opportunities
5.8.2 Market size and forecast, by region
5.8.3 Market analysis by country
CHAPTER 6: AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL
6.1 Overview
6.1.1 Market size and forecast
6.2 Hospital Pharmacies
6.2.1 Key market trends, growth factors and opportunities
6.2.2 Market size and forecast, by region
6.2.3 Market analysis by country
6.3 Drug Stores and Retail Pharmacies
6.3.1 Key market trends, growth factors and opportunities
6.3.2 Market size and forecast, by region
6.3.3 Market analysis by country
6.3.4 Drug Stores and Retail Pharmacies Amino acid Metabolism Disorders Treatment Market by Prescription type
6.3.4.1 Prescription drug Market size and forecast, by region
6.3.4.2 OTC drug Market size and forecast, by region
6.4 Online Providers
6.4.1 Key market trends, growth factors and opportunities
6.4.2 Market size and forecast, by region
6.4.3 Market analysis by country
CHAPTER 7: AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY REGION
7.1 Overview
7.1.1 Market size and forecast
7.2 North America
7.2.1 Key trends and opportunities
7.2.2 North America Market size and forecast, by Indication
7.2.3 North America Market size and forecast, by Product
7.2.4 North America Market size and forecast, by Distribution channel
7.2.4.1 North America Drug Stores and Retail Pharmacies Amino acid Metabolism Disorders Treatment Market by Prescription type
7.2.5 North America Market size and forecast, by country
7.2.5.1 U.S.
7.2.5.1.1 Market size and forecast, by Indication
7.2.5.1.2 Market size and forecast, by Product
7.2.5.1.3 Market size and forecast, by Distribution channel
7.2.5.2 Canada
7.2.5.2.1 Market size and forecast, by Indication
7.2.5.2.2 Market size and forecast, by Product
7.2.5.2.3 Market size and forecast, by Distribution channel
7.2.5.3 Mexico
7.2.5.3.1 Market size and forecast, by Indication
7.2.5.3.2 Market size and forecast, by Product
7.2.5.3.3 Market size and forecast, by Distribution channel
7.3 Europe
7.3.1 Key trends and opportunities
7.3.2 Europe Market size and forecast, by Indication
7.3.3 Europe Market size and forecast, by Product
7.3.4 Europe Market size and forecast, by Distribution channel
7.3.4.1 Europe Drug Stores and Retail Pharmacies Amino acid Metabolism Disorders Treatment Market by Prescription type
7.3.5 Europe Market size and forecast, by country
7.3.5.1 Germany
7.3.5.1.1 Market size and forecast, by Indication
7.3.5.1.2 Market size and forecast, by Product
7.3.5.1.3 Market size and forecast, by Distribution channel
7.3.5.2 France
7.3.5.2.1 Market size and forecast, by Indication
7.3.5.2.2 Market size and forecast, by Product
7.3.5.2.3 Market size and forecast, by Distribution channel
7.3.5.3 UK
7.3.5.3.1 Market size and forecast, by Indication
7.3.5.3.2 Market size and forecast, by Product
7.3.5.3.3 Market size and forecast, by Distribution channel
7.3.5.4 Italy
7.3.5.4.1 Market size and forecast, by Indication
7.3.5.4.2 Market size and forecast, by Product
7.3.5.4.3 Market size and forecast, by Distribution channel
7.3.5.5 Spain
7.3.5.5.1 Market size and forecast, by Indication
7.3.5.5.2 Market size and forecast, by Product
7.3.5.5.3 Market size and forecast, by Distribution channel
7.3.5.6 Rest of Europe
7.3.5.6.1 Market size and forecast, by Indication
7.3.5.6.2 Market size and forecast, by Product
7.3.5.6.3 Market size and forecast, by Distribution channel
7.4 Asia-Pacific
7.4.1 Key trends and opportunities
7.4.2 Asia-Pacific Market size and forecast, by Indication
7.4.3 Asia-Pacific Market size and forecast, by Product
7.4.4 Asia-Pacific Market size and forecast, by Distribution channel
7.4.4.1 Asia-Pacific Drug Stores and Retail Pharmacies Amino acid Metabolism Disorders Treatment Market by Prescription type
7.4.5 Asia-Pacific Market size and forecast, by country
7.4.5.1 Japan
7.4.5.1.1 Market size and forecast, by Indication
7.4.5.1.2 Market size and forecast, by Product
7.4.5.1.3 Market size and forecast, by Distribution channel
7.4.5.2 China
7.4.5.2.1 Market size and forecast, by Indication
7.4.5.2.2 Market size and forecast, by Product
7.4.5.2.3 Market size and forecast, by Distribution channel
7.4.5.3 Australia
7.4.5.3.1 Market size and forecast, by Indication
7.4.5.3.2 Market size and forecast, by Product
7.4.5.3.3 Market size and forecast, by Distribution channel
7.4.5.4 India
7.4.5.4.1 Market size and forecast, by Indication
7.4.5.4.2 Market size and forecast, by Product
7.4.5.4.3 Market size and forecast, by Distribution channel
7.4.5.5 South Korea
7.4.5.5.1 Market size and forecast, by Indication
7.4.5.5.2 Market size and forecast, by Product
7.4.5.5.3 Market size and forecast, by Distribution channel
7.4.5.6 Rest of Asia-Pacific
7.4.5.6.1 Market size and forecast, by Indication
7.4.5.6.2 Market size and forecast, by Product
7.4.5.6.3 Market size and forecast, by Distribution channel
7.5 LAMEA
7.5.1 Key trends and opportunities
7.5.2 LAMEA Market size and forecast, by Indication
7.5.3 LAMEA Market size and forecast, by Product
7.5.4 LAMEA Market size and forecast, by Distribution channel
7.5.4.1 LAMEA Drug Stores and Retail Pharmacies Amino acid Metabolism Disorders Treatment Market by Prescription type
7.5.5 LAMEA Market size and forecast, by country
7.5.5.1 Brazil
7.5.5.1.1 Market size and forecast, by Indication
7.5.5.1.2 Market size and forecast, by Product
7.5.5.1.3 Market size and forecast, by Distribution channel
7.5.5.2 Saudi Arabia
7.5.5.2.1 Market size and forecast, by Indication
7.5.5.2.2 Market size and forecast, by Product
7.5.5.2.3 Market size and forecast, by Distribution channel
7.5.5.3 South Africa
7.5.5.3.1 Market size and forecast, by Indication
7.5.5.3.2 Market size and forecast, by Product
7.5.5.3.3 Market size and forecast, by Distribution channel
7.5.5.4 Rest of LAMEA
7.5.5.4.1 Market size and forecast, by Indication
7.5.5.4.2 Market size and forecast, by Product
7.5.5.4.3 Market size and forecast, by Distribution channel
CHAPTER 8: COMPANY LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Key developments
CHAPTER 9: COMPANY PROFILES
9.1 AMINO GmbH
9.1.1 Company overview
9.1.2 Company snapshot
9.1.3 Operating business segments
9.1.4 Product portfolio
9.1.5 Business performance
9.1.6 Key strategic moves and developments
9.2 Civentichem, LLC, Ltd.
9.2.1 Company overview
9.2.2 Company snapshot
9.2.3 Operating business segments
9.2.4 Product portfolio
9.2.5 Business performance
9.2.6 Key strategic moves and developments
9.3 GlaxoSmithKline PLC
9.3.1 Company overview
9.3.2 Company snapshot
9.3.3 Operating business segments
9.3.4 Product portfolio
9.3.5 Business performance
9.3.6 Key strategic moves and developments
9.4 Koninklijke DSM N.V.
9.4.1 Company overview
9.4.2 Company snapshot
9.4.3 Operating business segments
9.4.4 Product portfolio
9.4.5 Business performance
9.4.6 Key strategic moves and developments
9.5 Kyowa Hakko Kirin Co., Ltd.
9.5.1 Company overview
9.5.2 Company snapshot
9.5.3 Operating business segments
9.5.4 Product portfolio
9.5.5 Business performance
9.5.6 Key strategic moves and developments
9.6 Merck KGaA
9.6.1 Company overview
9.6.2 Company snapshot
9.6.3 Operating business segments
9.6.4 Product portfolio
9.6.5 Business performance
9.6.6 Key strategic moves and developments
9.7 Pfizer, Inc.
9.7.1 Company overview
9.7.2 Company snapshot
9.7.3 Operating business segments
9.7.4 Product portfolio
9.7.5 Business performance
9.7.6 Key strategic moves and developments
9.8 Recordati S.p.A.
9.8.1 Company overview
9.8.2 Company snapshot
9.8.3 Operating business segments
9.8.4 Product portfolio
9.8.5 Business performance
9.8.6 Key strategic moves and developments
9.9 Sanofi
9.9.1 Company overview
9.9.2 Company snapshot
9.9.3 Operating business segments
9.9.4 Product portfolio
9.9.5 Business performance
9.9.6 Key strategic moves and developments
9.10 Shine Star (Hubei) Biological Engineering Co.
9.10.1 Company overview
9.10.2 Company snapshot
9.10.3 Operating business segments
9.10.4 Product portfolio
9.10.5 Business performance
9.10.6 Key strategic moves and developments
9.11 BioMarin Pharmaceutical Inc.
9.11.1 Company overview
9.11.2 Company snapshot
9.11.3 Operating business segments
9.11.4 Product portfolio
9.11.5 Business performance
9.11.6 Key strategic moves and developments
9.12 Teva Pharmaceutical Industries Ltd.
9.12.1 Company overview
9.12.2 Company snapshot
9.12.3 Operating business segments
9.12.4 Product portfolio
9.12.5 Business performance
9.12.6 Key strategic moves and developments
TABLE 1. GLOBAL AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 2. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, FOR PHENYLKETONURIA, BY REGION, 2021-2031 ($MILLION)
TABLE 3. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET FOR PHENYLKETONURIA, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 4. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, FOR MAPLE SYRUP URINE DISEASE, BY REGION, 2021-2031 ($MILLION)
TABLE 5. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET FOR MAPLE SYRUP URINE DISEASE, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 6. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, FOR CITRULLINEMIA, BY REGION, 2021-2031 ($MILLION)
TABLE 7. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET FOR CITRULLINEMIA, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 8. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, FOR HOMOCYSTINURIA, BY REGION, 2021-2031 ($MILLION)
TABLE 9. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET FOR HOMOCYSTINURIA, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 10. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, FOR ARGININOSUCCINIC ACIDURIA, BY REGION, 2021-2031 ($MILLION)
TABLE 11. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET FOR ARGININOSUCCINIC ACIDURIA, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 12. GLOBAL AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 13. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, FOR FOLIC ACID, BY REGION, 2021-2031 ($MILLION)
TABLE 14. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET FOR FOLIC ACID, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 15. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, FOR VITAMIN B6 AND B12, BY REGION, 2021-2031 ($MILLION)
TABLE 16. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET FOR VITAMIN B6 AND B12, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 17. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, FOR ARGININE, BY REGION, 2021-2031 ($MILLION)
TABLE 18. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET FOR ARGININE, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 19. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, FOR THIAMINE, BY REGION, 2021-2031 ($MILLION)
TABLE 20. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET FOR THIAMINE, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 21. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, FOR BETAINE, BY REGION, 2021-2031 ($MILLION)
TABLE 22. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET FOR BETAINE, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 23. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, FOR SAPROPTERIN, BY REGION, 2021-2031 ($MILLION)
TABLE 24. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET FOR SAPROPTERIN, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 25. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
TABLE 26. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 27. GLOBAL AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 28. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
TABLE 29. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 30. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
TABLE 31. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 32. GLOBAL DRUG STORES AND RETAIL PHARMACIES AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY PRESCRIPTION TYPE, 2021-2031 ($MILLION)
TABLE 33. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, FOR PRESCRIPTION DRUG, BY REGION, 2021-2031 ($MILLION)
TABLE 34. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, FOR OTC DRUG, BY REGION, 2021-2031 ($MILLION)
TABLE 35. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, FOR ONLINE PROVIDERS, BY REGION, 2021-2031 ($MILLION)
TABLE 36. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET FOR ONLINE PROVIDERS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 37. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY REGION, 2021-2031 ($MILLION)
TABLE 38. NORTH AMERICA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 39. NORTH AMERICA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 40. NORTH AMERICA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 41. NORTH AMERICA DRUG STORES AND RETAIL PHARMACIES AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY PRESCRIPTION TYPE, 2021-2031 ($MILLION)
TABLE 42. NORTH AMERICA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 43. U.S. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 44. U.S. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 45. U.S. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 46. CANADA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 47. CANADA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 48. CANADA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 49. MEXICO AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 50. MEXICO AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 51. MEXICO AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 52. EUROPE AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 53. EUROPE AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 54. EUROPE AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 55. EUROPE DRUG STORES AND RETAIL PHARMACIES AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY PRESCRIPTION TYPE, 2021-2031 ($MILLION)
TABLE 56. EUROPE AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 57. GERMANY AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 58. GERMANY AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 59. GERMANY AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 60. FRANCE AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 61. FRANCE AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 62. FRANCE AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 63. UK AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 64. UK AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 65. UK AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 66. ITALY AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 67. ITALY AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 68. ITALY AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 69. SPAIN AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 70. SPAIN AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 71. SPAIN AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 72. REST OF EUROPE AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 73. REST OF EUROPE AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 74. REST OF EUROPE AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 75. ASIA-PACIFIC AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 76. ASIA-PACIFIC AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 77. ASIA-PACIFIC AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 78. ASIA-PACIFIC DRUG STORES AND RETAIL PHARMACIES AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY PRESCRIPTION TYPE, 2021-2031 ($MILLION)
TABLE 79. ASIA-PACIFIC AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 80. JAPAN AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 81. JAPAN AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 82. JAPAN AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 83. CHINA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 84. CHINA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 85. CHINA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 86. AUSTRALIA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 87. AUSTRALIA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 88. AUSTRALIA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 89. INDIA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 90. INDIA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 91. INDIA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 92. SOUTH KOREA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 93. SOUTH KOREA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 94. SOUTH KOREA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 95. REST OF ASIA-PACIFIC AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 96. REST OF ASIA-PACIFIC AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 97. REST OF ASIA-PACIFIC AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 98. LAMEA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 99. LAMEA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 100. LAMEA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 101. LAMEA DRUG STORES AND RETAIL PHARMACIES AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY PRESCRIPTION TYPE, 2021-2031 ($MILLION)
TABLE 102. LAMEA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 103. BRAZIL AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 104. BRAZIL AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 105. BRAZIL AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 106. SAUDI ARABIA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 107. SAUDI ARABIA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 108. SAUDI ARABIA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 109. SOUTH AFRICA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 110. SOUTH AFRICA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 111. SOUTH AFRICA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 112. REST OF LAMEA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 113. REST OF LAMEA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 114. REST OF LAMEA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 115.AMINO GMBH: COMPANY SNAPSHOT
TABLE 116.AMINO GMBH: OPERATING SEGMENTS
TABLE 117.AMINO GMBH: PRODUCT PORTFOLIO
TABLE 118.AMINO GMBH: NET SALES,
TABLE 119.AMINO GMBH: KEY STRATERGIES
TABLE 120.CIVENTICHEM, LLC, LTD.: COMPANY SNAPSHOT
TABLE 121.CIVENTICHEM, LLC, LTD.: OPERATING SEGMENTS
TABLE 122.CIVENTICHEM, LLC, LTD.: PRODUCT PORTFOLIO
TABLE 123.CIVENTICHEM, LLC, LTD.: NET SALES,
TABLE 124.CIVENTICHEM, LLC, LTD.: KEY STRATERGIES
TABLE 125.GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
TABLE 126.GLAXOSMITHKLINE PLC: OPERATING SEGMENTS
TABLE 127.GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
TABLE 128.GLAXOSMITHKLINE PLC: NET SALES,
TABLE 129.GLAXOSMITHKLINE PLC: KEY STRATERGIES
TABLE 130.KONINKLIJKE DSM N.V.: COMPANY SNAPSHOT
TABLE 131.KONINKLIJKE DSM N.V.: OPERATING SEGMENTS
TABLE 132.KONINKLIJKE DSM N.V.: PRODUCT PORTFOLIO
TABLE 133.KONINKLIJKE DSM N.V.: NET SALES,
TABLE 134.KONINKLIJKE DSM N.V.: KEY STRATERGIES
TABLE 135.KYOWA HAKKO KIRIN CO., LTD.: COMPANY SNAPSHOT
TABLE 136.KYOWA HAKKO KIRIN CO., LTD.: OPERATING SEGMENTS
TABLE 137.KYOWA HAKKO KIRIN CO., LTD.: PRODUCT PORTFOLIO
TABLE 138.KYOWA HAKKO KIRIN CO., LTD.: NET SALES,
TABLE 139.KYOWA HAKKO KIRIN CO., LTD.: KEY STRATERGIES
TABLE 140.MERCK KGAA: COMPANY SNAPSHOT
TABLE 141.MERCK KGAA: OPERATING SEGMENTS
TABLE 142.MERCK KGAA: PRODUCT PORTFOLIO
TABLE 143.MERCK KGAA: NET SALES,
TABLE 144.MERCK KGAA: KEY STRATERGIES
TABLE 145.PFIZER, INC.: COMPANY SNAPSHOT
TABLE 146.PFIZER, INC.: OPERATING SEGMENTS
TABLE 147.PFIZER, INC.: PRODUCT PORTFOLIO
TABLE 148.PFIZER, INC.: NET SALES,
TABLE 149.PFIZER, INC.: KEY STRATERGIES
TABLE 150.RECORDATI S.P.A.: COMPANY SNAPSHOT
TABLE 151.RECORDATI S.P.A.: OPERATING SEGMENTS
TABLE 152.RECORDATI S.P.A.: PRODUCT PORTFOLIO
TABLE 153.RECORDATI S.P.A.: NET SALES,
TABLE 154.RECORDATI S.P.A.: KEY STRATERGIES
TABLE 155.SANOFI: COMPANY SNAPSHOT
TABLE 156.SANOFI: OPERATING SEGMENTS
TABLE 157.SANOFI: PRODUCT PORTFOLIO
TABLE 158.SANOFI: NET SALES,
TABLE 159.SANOFI: KEY STRATERGIES
TABLE 160.SHINE STAR (HUBEI) BIOLOGICAL ENGINEERING CO.: COMPANY SNAPSHOT
TABLE 161.SHINE STAR (HUBEI) BIOLOGICAL ENGINEERING CO.: OPERATING SEGMENTS
TABLE 162.SHINE STAR (HUBEI) BIOLOGICAL ENGINEERING CO.: PRODUCT PORTFOLIO
TABLE 163.SHINE STAR (HUBEI) BIOLOGICAL ENGINEERING CO.: NET SALES,
TABLE 164.SHINE STAR (HUBEI) BIOLOGICAL ENGINEERING CO.: KEY STRATERGIES
TABLE 165.BIOMARIN PHARMACEUTICAL INC.: COMPANY SNAPSHOT
TABLE 166.BIOMARIN PHARMACEUTICAL INC.: OPERATING SEGMENTS
TABLE 167.BIOMARIN PHARMACEUTICAL INC.: PRODUCT PORTFOLIO
TABLE 168.BIOMARIN PHARMACEUTICAL INC.: NET SALES,
TABLE 169.BIOMARIN PHARMACEUTICAL INC.: KEY STRATERGIES
TABLE 170.TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
TABLE 171.TEVA PHARMACEUTICAL INDUSTRIES LTD.: OPERATING SEGMENTS
TABLE 172.TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
TABLE 173.TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET SALES,
TABLE 174.TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATERGIES
*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/